916902-55-1

Usage

Uses

Used in Organic Synthesis:
6-Hydroxymethyl-1H-indazole is used as a key intermediate in the synthesis of complex organic molecules. Its unique structure allows for versatile chemical reactions, facilitating the creation of a wide range of compounds with diverse properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-Hydroxymethyl-1H-indazole is utilized as a building block for the development of pharmaceutical compounds. Its chemical properties make it a promising candidate for the design of new drugs with potential therapeutic applications.
Used in Pharmaceutical Compounds Synthesis:
6-Hydroxymethyl-1H-indazole is employed as a fundamental component in the synthesis of various pharmaceutical compounds. Its presence in these compounds can contribute to their efficacy, safety, and pharmacokinetic properties, making it an essential part of drug discovery and development processes.
While specific applications in different industries are not provided in the materials, the general uses outlined above reflect the compound's potential across various sectors within the pharmaceutical and chemical industries.

InChI:InChI=1/C8H8N2O/c11-5-6-1-2-7-4-9-10-8(7)3-6/h1-4,11H,5H2,(H,9,10)

Upstream product

• 713-09-7 ethyl 1H-indazole-6-carboxylate 
• 724-43-6 ethyl 1-acetyl-1H-indazole-6-carboxylate 
• 704-91-6 1H-indazole-6-carboxylic acid 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 2458-12-0 3-amino-p-toluic acid 

Downstream Products

• 152626-91-0 6-(bromomethyl)-1H-indazole 
• 944904-42-1 3-iodo-1H-indazole-6-carbaldehyde 
• 669050-69-5 1H-indazole-6-carboxyaldehyde 

Relevant academic research and scientific papers

PESTICIDAL COMPOUNDS

The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, (I). The compounds of formula (I), as well as the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof, are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

Expedient Synthesis of Thioether-Functionalized Hydrotris(indazolyl)borate as an Anchoring Platform for Rotary Molecular Machines

Major improvements in the synthesis of surface-mounted rotary molecular machines based on ruthenium(II) complexes are reported. The development of a one-pot indium(III)-mediated “N-deprotection/ester reductive sulfidation” sequence allowed step economy, reproducibility and high efficiency in the synthesis of the thioether-functionalized tripodal ligand. Switching to the thallium salt of hydrotris(indazolyl)borate and to microwave heating further optimized the preparation of the common intermediate in the modular synthesis of symmetric and dissymmetric molecular motors and gears. The penta(4-bromophenyl)cyclopentadienyl ruthenium(II) key precursor is now reproducibly synthesized in 5 steps and 31 % overall yield on the longest linear sequence. Subsequent fivefold Suzuki–Miyaura coupling with ferroceneboronic acid led to a new C5-symmetric pentaferrocenyl molecular motor.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS

The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phospho

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

Synthesis of new tripodal tri-functionalized hydrotris(indazol-1-yl)borate ligands and x-ray structures of their cyclopentadieneruthenium complexes

Two new tripodal ligands designed to anchor complexes onto surfaces have been synthesized. They integrate ester or thioether functions at the 6-position of the indazoles. Potassium hydrotris[6-(ethoxycarbonyl)indazolyl]borate and potassium hydrotris{6-[(ethylsulfanyl)methyl]indazolyl}borate exhibit three pendant groups oriented to anchor complexes onto an oxide and a metallic surface, respectively. Their complexation with [RuCp(CH3CN) 3]PF6 yielded two piano-stool-shaped complexes that were characterized by X-ray diffraction. Comparison with the synthesized unfunctionalized analog showed that the three 6-substituted functions do not interfere with the coordination site and are particularly well oriented for surface deposition. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.

MODULATORS OF CELLULAR ADHESION

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).